Lung Cancers Today
Advertisement
Kathryn C. Arbour, MD, of the Memorial Sloan Kettering Cancer Center, presented results from the study at AACR 2025.
Margarita Majem, MD, PhD, presented the results as a late-breaking abstract during the European Lung Cancer Congress 2025.
PALOMA-2 used data from PALOMA-3 to evaluate subcutaneous versus intravenous amivantamab for EGFR-mutated NSCLC.
The phase 3 DeLLphi-304 trial of tarlatamab versus standard-of-care chemotherapy has met its primary end point.
The session covered everything from new actionable immune checkpoints to vaccines, cellular therapies, and bispecifics.
Dr. Ladanyi reflects on genetic hotspot mutations that have not been previously well characterized in lung adenocarcinoma.
Martin Reck, MD, PhD, reflects on key updates in stage III NSCLC from the European Lung Cancer Congress 2025.
Stephen V. Liu, MD, weighs in on the data from the preplanned interim analysis that was recently published in The Lancet.
The study is evaluating regimens to prevent dermatologic adverse events in patients receiving amivantamab plus lazertinib.
Final overall survival data from the phase 3 study demonstrated significant benefits for patients with EGFR-mutated aNSCLC.
The study authors evaluated the physical, psychosocial, and lifestyle challenges faced by patients with lung cancer.
Most patients with MPM experience pleural effusion, but questions remain about the condition's impact on patient outcomes.
The NCCN 2025 Annual Conference will be held from March 28-30 in Orlando, Florida.
Expanded treatment options for pleural mesothelioma are "urgently needed," due to the high morbidity of the disease.
Learn how researchers determined the best treatment strategy for smoking cessation among patients who currently smoke.
Clinicians hypothesize that the genetic mutation, known as RUFY1-RET fusion, caused resistance to lorlatinib.
Researchers evaluated if demographics, clinical characteristics, and outcomes varied between those with KRAS G12C and G12D.
The therapy is currently under evaluation in phase 1 and phase 2 trials.
A distributed clinical trial is analyzing diet and exercise patterns in young people with lung cancer.
The Prescription Drug User Fee Act action date is expected in the third quarter of 2025.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.